Why the study?
Do biodegradable polymer drug-eluting stents reduce MACE compared to durable polymer sirolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction?
Population
497 patients with acute ST-segment elevation myocardial infarction pooled from three randomized clinical…
Comparison
Biodegradable polymer drug-eluting stents (BP-DES) vs Durable polymer sirolimus-eluting stents (DP-SES)
Design
Meta-analysis
Follow-up
4 years
Authors
Loading...
Supports BP-DES preference in STEMI to reduce 4-year MACE; extends meta-analytic evidence to longer-term outcomes.
Do biodegradable polymer drug-eluting stents reduce MACE compared to durable polymer sirolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction?
In patients with STEMI, biodegradable polymer drug-eluting stents significantly reduced the risk of MACE at 4 years compared to durable polymer sirolimus-eluting stents, primarily driven by reduced target lesion revascularization.
Waha et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: